Cell & Gene Therapy Commercialization: Overcoming Manufacturing, Market Access, and Scale Challenges

Cell and gene therapies (CGTs) are changing the pharmaceutical industry by introducing new approaches to treating cancer, genetic disorders, rare diseases, and other serious conditions. However, translating scientific innovation into commercially sustainable treatments requires pharmaceutical companies to address challenges that differ significantly from those associated with traditional small molecules and biologics.

Cell and gene therapy commercialization involves much more than regulatory approval. Manufacturing scalability, market access, reimbursement, patient identification, specialized treatment infrastructure, supply-chain coordination, and long-term value demonstration all influence the commercial potential of these therapies.

For pharma companies, developing a cell and gene therapy commercialization strategy early can help connect clinical development with manufacturing, regulatory planning, commercial strategy, and patient access.

Cell and gene therapy commercialization is the process of moving a CGT from clinical development and regulatory approval into sustainable commercial use. It encompasses manufacturing, regulatory strategy, market access, reimbursement, distribution, patient identification, healthcare-provider readiness, and treatment delivery.

By comparison, CGTs can require:

• Highly specialized manufacturing facilities
• Complex quality-control processes
• Patient-specific or time-sensitive production
• Specialized treatment centers
• Advanced logistics
• Long-term patient monitoring
• New reimbursement approaches
• Strong coordination between manufacturers and healthcare providers

These characteristics create significant cell and gene therapy commercialization challenges.

The commercial model can also vary according to the type of therapy. Cell therapy commercialization may involve patient-specific collection, manufacturing, and reinfusion, while gene therapy commercialization may involve viral vectors, genetic modification, specialized administration, and long-term follow-up.

Understanding these differences is essential when developing a CGT commercialization strategy.

Key considerations include:

• Production capacity
• Process consistency
• Manufacturing cost
• Quality control
• Automation
• Facility requirements
• Workforce availability
• Supply reliability
• Regulatory compliance

Consequently, cell and gene therapy manufacturing scalability challenges must be considered alongside clinical and commercial planning rather than treated solely as manufacturing issues.

Developing effective strategies for scaling cell and gene therapy manufacturing requires companies to evaluate technology, infrastructure, workforce, process standardization, and quality systems simultaneously.

For CGT manufacturing, automation can reduce manual intervention and improve process consistency. Smaller manufacturing footprints, automated quality control, improved analytics, and standardized workflows may also help manufacturers improve efficiency.

The source material identifies automation, improved analytical capabilities, process transparency, and reliability as important areas for improving manufacturing operations.

For cell therapy manufacturing, scalability can be particularly complex when products require patient-specific production.

The cell and gene therapy supply chain can involve patient identification, sample collection, transportation, manufacturing, quality testing, product release, delivery to treatment centers, administration, and patient monitoring.

For personalized cell therapies, these steps may need to be coordinated within highly controlled timeframes.

This creates significant cell and gene therapy supply chain challenges, particularly when therapies have limited stability or require rapid movement between manufacturing facilities and treatment centers.

The cell therapy supply chain therefore needs to be designed around the specific characteristics of the therapy.

A successful commercialization model should consider:

Off-the-shelf approaches could potentially simplify aspects of manufacturing and distribution, although they also introduce scientific, clinical, manufacturing, and regulatory considerations.

For companies evaluating these platforms, the commercial question is not simply whether a therapy can be manufactured at scale, but whether its manufacturing model can support reliable patient access and sustainable economics.

Regulation is another fundamental component of commercialization.

A robust cell and gene therapy regulatory strategy needs to address manufacturing controls, product characterization, clinical evidence, quality requirements, safety, and long-term follow-up.

The FDA has continued to develop its regulatory approach to CGTs. In 2026, the agency introduced additional guidance and flexibility around chemistry, manufacturing, and controls (CMC), while also providing guidance covering regulatory review and other aspects of CGT development.

Cell and gene therapy market access challenges can arise from high treatment costs, limited treatment-center capacity, complex administration requirements, small eligible patient populations, and uncertainty around long-term outcomes.

Pharma companies therefore need to evaluate cell and gene therapy market access during development rather than waiting until launch.

Important considerations include:

• Eligible patient populations
• Treatment pathways
• Healthcare infrastructure
• Payer requirements
• Clinical outcomes
• Cost-effectiveness
• Reimbursement mechanisms
• Provider readiness
• Patient identification

These factors directly influence CGT market access and the ability of patients to receive innovative therapies.

• Outcomes-based agreements
• Value-based arrangements
• Alternative payment models
• Risk-sharing approaches
• Payer evidence development
• Long-term outcomes monitoring

The appropriate approach will depend on the therapy, indication, healthcare system, payer environment, and available clinical evidence.

Patient identification is another important commercialization consideration.